FDA Approves LISDEXAMFETAMINE DIMESYLATE — Camber Pharmaceuticals, Inc.

# FDA Approves Generic Version of Lisdexamfetamine Dimesylate Camber Pharmaceuticals, Inc. received FDA approval for its generic formulation of lisdexamfetamine dimesylate on August 25, 2023, introducing competition to the branded ADHD treatment market and potentially lowering costs for patients and insurers. The approval of the oral generic is expected to capture meaningful market share from the branded version, which has historically commanded significant sales in the attention-deficit/hyperactivity disorder therapeutic segment.